Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
2,076 rows where has_cryoEM = 0, in_cev_map = 0 and tier = "Tier 1.5" sorted by evidence_priority descending
This data as json, CSV (advanced)
Suggested facets: pdb_count_total
surface_class 5
- B_cargo 1,076
- unknown 436
- A_surface 305
- A_assoc 164
- A2_pm_peripheral 95
tier 1
- Tier 1.5 · 2,076 ✖
in_cev_map 1
- - · 2,076 ✖
has_cryoEM 1
- - · 2,076 ✖
has_activation_state_pdb_pair 1
- 0 2,076
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| O95255 | ABCC6 | ATP-binding cassette sub-family C member 6 | Tier 1.5 | 0.809 | 1 | A_surface | 4 | 80.94 | 0 | 0 | 0 | 0 | 0 | Pseudoxanthoma elasticum | 0.864631668818611 | |||
| P30968 | GNRHR | Gonadotropin-releasing hormone receptor | Tier 1.5 | 0.799 | 1 | A_surface | 1 | 84.19 | 0 | 0 | 0 | 0 | 0 | hypogonadotropic hypogonadism | 0.83100005285263 | |||
| P10912 | GHR | Growth hormone receptor | Tier 1.5 | 0.799 | 1 | A_surface | 9 | 58.69 | 0 | 0 | 1 | 5 | 38811951, 38477735, 31603904 | 0 | Laron syndrome | 0.8304020079647765 | ||
| O43525 | KCNQ3 | Potassium voltage-gated channel subfamily KQT member 3 | Tier 1.5 | 0.789 | 1 | A_surface | 1 | 56.72 | 0 | 0 | 0 | 0 | 0 | Benign familial neonatal seizures | 0.7961763561533409 | |||
| P37023 | ACVRL1 | Activin receptor type-1-like | Tier 1.5 | 0.789 | 1 | A_surface | 7 | 82.0 | 0 | 0 | 0 | 0 | 0 | telangiectasia, hereditary hemorrhagic, type 2 | 0.7951167515831324 | |||
| P16410 | CTLA4 | Cytotoxic T-lymphocyte protein 4 | Tier 1.5 | 0.787 | 1 | A_surface | 22 | 80.12 | 0 | 0 | 1 | 26 | 41907643, 40972397, 40870970, 40811947, 40536609, 39417693, 38473398, 38158454, 36966395, 36831533, 36603108, 36015348, 33970170, 32929022, 32840510, 32280743, 32024070, 31405808, 28918052, 28082399, 26030229, 25565435, 24892807, 23460536, 23460531, 14612549 | 0 | autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency | 0.7906408646569979 | ||
| Q13698 | CACNA1S | Voltage-dependent L-type calcium channel subunit alpha-1S | Tier 1.5 | 0.786 | 1 | A_surface | 2 | 71.81 | 0 | 0 | 0 | 0 | 0 | hypokalemic periodic paralysis, type 1 | 0.7869997029542154 | |||
| Q96MS0 | ROBO3 | Roundabout homolog 3 | Tier 1.5 | 0.784 | 1 | A_surface | 3 | 63.69 | 0 | 0 | 1 | 2 | 32369590 | 0 | horizontal gaze palsy with progressive scoliosis | 0.7813306356858872 | ||
| Q8TDI8 | TMC1 | Transmembrane channel-like protein 1 | Tier 1.5 | 0.781 | 1 | A_surface | 1 | 76.88 | 0 | 0 | 0 | 0 | 0 | autosomal recessive nonsyndromic hearing loss 7 | 0.7694318181814068 | |||
| Q9NUN7 | ACER3 | Alkaline ceramidase 3 | Tier 1.5 | 0.777 | 1 | A_surface | 2 | 93.19 | 0 | 0 | 0 | 0 | 0 | alkaline ceramidase 3 deficiency | 0.7575827142824458 | |||
| P40126 | DCT | L-dopachrome tautomerase | Tier 1.5 | 0.774 | 1 | A_surface | 1 | 89.12 | 0 | 0 | 1 | 1 | 27245069 | 0 | oculocutaneous albinism type 8 | 0.7468868816172217 | ||
| Q9Y6J6 | KCNE2 | Potassium voltage-gated channel subfamily E member 2 | Tier 1.5 | 0.772 | 1 | A_surface | 1 | 78.25 | 0 | 0 | 0 | 0 | 0 | Romano-Ward syndrome | 0.739531738338193 | |||
| O43914 | TYROBP | TYRO protein tyrosine kinase-binding protein | Tier 1.5 | 0.77 | 1 | A_surface | 5 | 64.62 | 0 | 0 | 0 | 0 | 0 | Nasu-Hakola disease | 0.7323368313860329 | |||
| P48023 | FASLG | Tumor necrosis factor ligand superfamily member 6 | Tier 1.5 | 0.76 | 1 | A_surface | 3 | 80.19 | 0 | 0 | 1 | 1 | 16581027 | 0 | autoimmune lymphoproliferative syndrome type 1 | 0.6984292519156657 | ||
| O00305 | CACNB4 | Voltage-dependent L-type calcium channel subunit beta-4 | Tier 1.5 | 0.757 | 1 | A_surface | 1 | 71.81 | 0 | 0 | 0 | 0 | 0 | episodic ataxia type 5 | 0.6883498385715039 | |||
| Q13002 | GRIK2 | Glutamate receptor ionotropic, kainate 2 | Tier 1.5 | 0.757 | 1 | A_surface | 2 | 83.56 | 0 | 0 | 0 | 0 | 0 | intellectual disability, autosomal recessive 6 | 0.6913183275248935 | |||
| Q9UL01 | DSE | Dermatan-sulfate epimerase | Tier 1.5 | 0.755 | 1 | A_surface | 1 | 86.56 | 0 | 0 | 0 | 0 | 0 | Ehlers-Danlos syndrome, musculocontractural type | 0.6849286764746361 | |||
| P32970 | CD70 | CD70 antigen | Tier 1.5 | 0.75 | 1 | A_surface | 1 | 83.19 | 0 | 0 | 1 | 1 | 30609550 | 0 | severe combined immunodeficiency due to CD70 deficiency | 0.6651491980619259 | ||
| Q9HCK4 | ROBO2 | Roundabout homolog 2 | Tier 1.5 | 0.744 | 1 | A_surface | 6 | 67.38 | 0 | 0 | 1 | 2 | 40616090, 31640794 | 0 | familial vesicoureteral reflux | 0.6460375744556555 | ||
| Q8N126 | CADM3 | Cell adhesion molecule 3 | Tier 1.5 | 0.735 | 1 | A_surface | 1 | 84.38 | 0 | 0 | 1 | 2 | 39263947 | 0 | Charcot-Marie-Tooth disease, axonal, type 2FF | 0.6157861516342734 | ||
| Q15399 | TLR1 | Toll-like receptor 1 | Tier 1.5 | 0.729 | 1 | A_surface | 6 | 87.19 | 0 | 0 | 0 | 0 | 0 | asthma | 0.5956884825296496 | |||
| Q15822 | CHRNA2 | Neuronal acetylcholine receptor subunit alpha-2 | Tier 1.5 | 0.727 | 1 | A_surface | 1 | 77.0 | 0 | 0 | 0 | 0 | 0 | autosomal dominant nocturnal frontal lobe epilepsy | 0.5887530831976572 | |||
| P21709 | EPHA1 | Ephrin type-A receptor 1 | Tier 1.5 | 0.724 | 1 | A_surface | 4 | 80.38 | 0 | 0 | 1 | 4 | 35283197, 24629635, 41325160 | 0 | Alzheimer disease | 0.5784090512493305 | ||
| O75888 | TNFSF13 | Tumor necrosis factor ligand superfamily member 13 | Tier 1.5 | 0.723 | 1 | A_surface | 1 | 81.19 | 0 | 0 | 0 | 0 | 0 | IGA glomerulonephritis | 0.5756611141862813 | |||
| P31358 | CD52 | CAMPATH-1 antigen | Tier 1.5 | 0.723 | 1 | A_surface | 1 | 67.19 | 0 | 0 | 1 | 1 | 39865939 | 0 | chronic lymphocytic leukemia | 0.5770414699711784 | ||
| Q9Y2K2 | SIK3 | Serine/threonine-protein kinase SIK3 | Tier 1.5 | 0.717 | 1 | A_surface | 5 | 50.66 | 0 | 0 | 0 | 0 | 0 | Spondyloepiphyseal dysplasia and spondyloepimetaphyseal dysplasia | 0.5576394742765879 | |||
| Q68D85 | NCR3LG1 | Natural cytotoxicity triggering receptor 3 ligand 1 | Tier 1.5 | 0.712 | 1 | A_surface | 4 | 77.62 | 0 | 0 | 0 | 0 | 0 | Abnormality of the skeletal system | 0.539257633627721 | |||
| Q16821 | PPP1R3A | Protein phosphatase 1 regulatory subunit 3A | Tier 1.5 | 0.708 | 1 | A_surface | 1 | 44.66 | 0 | 0 | 0 | 0 | 0 | type 2 diabetes mellitus | 0.5280839677306426 | |||
| Q01151 | CD83 | CD83 antigen | Tier 1.5 | 0.707 | 1 | A_surface | 4 | 72.56 | 0 | 0 | 0 | 0 | 0 | rheumatoid arthritis | 0.5217195398123413 | |||
| O43653 | PSCA | Prostate stem cell antigen | Tier 1.5 | 0.706 | 1 | A_surface | 1 | 81.31 | 0 | 0 | 1 | 2 | 41911185 | 0 | duodenal ulcer | 0.5197329863180171 | ||
| O95256 | IL18RAP | Interleukin-18 receptor accessory protein | Tier 1.5 | 0.698 | 1 | A_surface | 3 | 77.81 | 0 | 0 | 0 | 0 | 0 | asthma | 0.494046797330986 | |||
| P35590 | TIE1 | Tyrosine-protein kinase receptor Tie-1 | Tier 1.5 | 0.695 | 1 | A_surface | 1 | 80.81 | 0 | 0 | 1 | 1 | 35045701 | 0 | lymphatic malformation 11 | 0.4838261303064323 | ||
| Q9Y2C9 | TLR6 | Toll-like receptor 6 | Tier 1.5 | 0.694 | 1 | A_surface | 1 | 85.81 | 0 | 0 | 0 | 0 | 0 | response to stimulus | 0.4801931545173786 | |||
| A8MYU2 | KCNU1 | Potassium channel subfamily U member 1 | Tier 1.5 | 0.693 | 1 | A_surface | 1 | 74.25 | 0 | 0 | 0 | 0 | 0 | type 2 diabetes mellitus | 0.47664025348421396 | |||
| P31994 | FCGR2B | Low affinity immunoglobulin gamma Fc region receptor II-b | Tier 1.5 | 0.688 | 1 | A_surface | 5 | 78.44 | 0 | 0 | 1 | 1 | 38928037 | 0 | systemic lupus erythematosus | 0.460465747544726 | ||
| P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | Tier 1.5 | 0.688 | 1 | A_surface | 7 | 81.69 | 0 | 0 | 0 | 0 | 0 | breast carcinoma | 0.46059757867639306 | |||
| Q6ZMJ2 | SCARA5 | Scavenger receptor class A member 5 | Tier 1.5 | 0.687 | 1 | A_surface | 1 | 71.5 | 0 | 0 | 0 | 0 | 0 | venous thromboembolism | 0.457784641474775 | |||
| Q13253 | NOG | Noggin | Tier 1.5 | 0.685 | 1 | A_assoc | 2 | 86.06 | 0 | 0 | 1 | 2 | 38397086 | 0 | proximal symphalangism 1A | 0.7844136456463046 | ||
| Q86XE3 | MICU3 | Calcium uptake protein 3, mitochondrial | Tier 1.5 | 0.684 | 1 | A_surface | 2 | 71.25 | 0 | 0 | 1 | 1 | 26318819 | 0 | neurodegenerative disease | 0.4480613767359447 | ||
| P01138 | NGF | Beta-nerve growth factor | Tier 1.5 | 0.684 | 1 | A_assoc | 8 | 73.25 | 0 | 0 | 1 | 6 | 42015870, 38780008, 32982626, 21216401, 7545283, 29754498 | 0 | hereditary sensory and autonomic neuropathy type 5 | 0.7785402119369383 | ||
| P18510 | IL1RN | Interleukin-1 receptor antagonist protein | Tier 1.5 | 0.682 | 1 | A_assoc | 5 | 87.06 | 0 | 0 | 1 | 1 | 38928037 | 0 | sterile multifocal osteomyelitis with periostitis and pustulosis | 0.7734282711738736 | ||
| Q9ULX7 | CA14 | Carbonic anhydrase 14 | Tier 1.5 | 0.682 | 1 | A_surface | 2 | 90.69 | 0 | 0 | 0 | 0 | 0 | epilepsy | 0.4397024990575866 | |||
| P29120 | PCSK1 | Neuroendocrine convertase 1 | Tier 1.5 | 0.682 | 1 | A_assoc | 3 | 82.5 | 0 | 0 | 0 | 0 | 0 | obesity due to prohormone convertase I deficiency | 0.773875795833803 | |||
| Q9BQ51 | PDCD1LG2 | Programmed cell death 1 ligand 2 | Tier 1.5 | 0.678 | 1 | A_surface | 2 | 86.38 | 0 | 0 | 1 | 1 | 38928037 | 0 | melanoma | 0.42716921377769757 | ||
| O14917 | PCDH17 | Protocadherin-17 | Tier 1.5 | 0.678 | 1 | A_surface | 1 | 67.69 | 0 | 0 | 0 | 0 | 0 | intelligence | 0.42768901986983704 | |||
| P16112 | ACAN | Aggrecan core protein | Tier 1.5 | 0.677 | 1 | A_assoc | 4 | 51.91 | 0 | 0 | 0 | 0 | 0 | Familial osteochondritis dissecans | 0.7558487616449627 | |||
| P55789 | GFER | FAD-linked sulfhydryl oxidase ALR | Tier 1.5 | 0.677 | 1 | A_assoc | 7 | 76.88 | 0 | 0 | 0 | 0 | 0 | congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome | 0.7556346526616893 | |||
| Q8TD46 | CD200R1 | Cell surface glycoprotein CD200 receptor 1 | Tier 1.5 | 0.676 | 1 | A_surface | 1 | 74.56 | 0 | 0 | 1 | 4 | 35359946, 31811336, 30195773, 25158092 | 0 | atopic eczema | 0.4186418842135947 | ||
| P05177 | CYP1A2 | Cytochrome P450 1A2 | Tier 1.5 | 0.674 | 1 | A_surface | 1 | 95.56 | 0 | 0 | 1 | 1 | 22554528 | 0 | hypertension | 0.41351893759794517 | ||
| Q86YL7 | PDPN | Podoplanin | Tier 1.5 | 0.674 | 1 | A_surface | 6 | 57.97 | 0 | 0 | 1 | 4 | 41304780, 41292412, 39451677 | 0 | Microscopic hematuria | 0.41183796492083136 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;